Study wrapper · #454
Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
Editor's note
A PRISMA-based systematic review of 15 studies on approved anti-obesity pharmacotherapies, with a focus on GLP-1 and dual incretin agents. For tracked peptides it reports dose-dependent weight loss, semaglutide 2.4 mg around -15%, tirzepatide roughly -15% to -18.5%, alongside glycemic and cardiometabolic improvements (HbA1c, blood pressure, LDL) and predominantly mild gastrointestinal adverse events, with serious events, pancreatitis and gallbladder complications described as rare and discontinuation generally under 15%. As a qualitative systematic review it synthesizes rather than pools data, so it lacks the quantitative rigor of a meta-analysis, and the 15-study base spans heterogeneous populations. The findings are consistent with the broader trial record for semaglutide and tirzepatide. Read as a solid orienting summary of where these agents stand on weight and cardiometabolic measures, with the usual caveat that review-level synthesis is only as strong as its included studies.
Plain-language abstract
This review pulled together 15 studies to summarize how well approved weight-loss drugs work and how safe they are, focusing on GLP-1 drugs and dual-action drugs. It found that weight loss depended on the dose: semaglutide produced about 15% weight loss, tirzepatide about 15 to 18.5%, and combined GIP/GLP-1 therapy up to about 21%. Along with weight loss, people saw improvements in blood sugar, blood pressure and cholesterol. Side effects were mostly mild stomach and bowel problems such as nausea, vomiting and diarrhea, while serious problems, including pancreas inflammation and gallbladder issues, were rare, and fewer than 15% of people generally stopped treatment. The authors conclude these drugs offer substantial, dose-related weight loss with added heart-and-metabolism benefits and are generally well tolerated. Because this is a summary of varied studies rather than a pooled statistical analysis, its strength depends on the quality of the studies it included, but the findings match what larger trials have shown.